Unknown

Dataset Information

0

A vaccine directed to B cells and produced by cell-free protein synthesis generates potent antilymphoma immunity.


ABSTRACT: Clinical studies of idiotype (Id) vaccination in patients with lymphoma have established a correlation between the induced anti-Id antibody responses and favorable clinical outcomes. To streamline the production of an Id vaccine, we engineered a small diabody (Db) molecule containing both a B-cell-targeting moiety (anti-CD19) and a lymphoma Id. This molecule (?CD19-Id) was designed to penetrate lymph nodes and bind to noncognate B cells to form an antigen presentation array. Indeed, the ?CD19-Id molecule accumulated on B cells in vivo after s.c. administration. These noncognate B cells, decorated with the diabody, could then stimulate the more rare Id-specific B cells. Peptide epitopes present in the diabody linker augmented the response by activating CD4(+) helper T cells. Consequently, the ?CD19-Id molecule induced a robust Id-specific antibody response and protected animals from tumor challenge. Such diabodies are produced in a cell-free protein expression system within hours of amplification of the specific Ig genes from the B-cell tumor. This customized product can now be available to vaccinate patients before they receive other, potentially immunosuppressive, therapies.

SUBMITTER: Ng PP 

PROVIDER: S-EPMC3437846 | biostudies-other | 2012 Sep

REPOSITORIES: biostudies-other

altmetric image

Publications

A vaccine directed to B cells and produced by cell-free protein synthesis generates potent antilymphoma immunity.

Ng Patrick P PP   Jia Ming M   Patel Kedar G KG   Brody Joshua D JD   Swartz James R JR   Levy Shoshana S   Levy Ronald R  

Proceedings of the National Academy of Sciences of the United States of America 20120808 36


Clinical studies of idiotype (Id) vaccination in patients with lymphoma have established a correlation between the induced anti-Id antibody responses and favorable clinical outcomes. To streamline the production of an Id vaccine, we engineered a small diabody (Db) molecule containing both a B-cell-targeting moiety (anti-CD19) and a lymphoma Id. This molecule (αCD19-Id) was designed to penetrate lymph nodes and bind to noncognate B cells to form an antigen presentation array. Indeed, the αCD19-Id  ...[more]

Similar Datasets

| S-EPMC1976361 | biostudies-literature
| S-EPMC7877766 | biostudies-literature
| S-EPMC5986796 | biostudies-other
2021-12-23 | GSE183941 | GEO
| S-EPMC4373413 | biostudies-literature
| S-EPMC3171992 | biostudies-other
| S-EPMC2917173 | biostudies-literature
| S-EPMC6030477 | biostudies-literature
| S-EPMC8284974 | biostudies-literature
| S-EPMC3842990 | biostudies-literature